Qiagen (QGEN) Expected to Post Quarterly Earnings on Wednesday

Qiagen (NYSE:QGEN) is anticipated to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Qiagen to post earnings of $0.6270 per share and revenue of $538.61 million for the quarter. Qiagen has set its FY 2026 guidance at 2.430- EPS. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:30 AM ET.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.60 by $0.02. The company had revenue of $535.04 million during the quarter, compared to analysts’ expectations of $527.50 million. During the same period in the previous year, the business earned $0.60 earnings per share. The business’s revenue for the quarter was up .2% compared to the same quarter last year. On average, analysts expect Qiagen to post $2.44 EPS for the current fiscal year and $2.61 EPS for the next fiscal year.

Qiagen Trading Down 0.3%

NYSE:QGEN opened at $50.20 on Wednesday. Qiagen has a 12 month low of $32.53 and a 12 month high of $57.81. The firm has a fifty day simple moving average of $44.73 and a 200-day simple moving average of $42.70.

Wall Street Analysts Forecast Growth

Several analysts recently commented on QGEN shares. Barclays set a $40.00 target price on Qiagen and gave the stock an “equal weight” rating in a report on Friday, August 7th. Robert W. Baird raised their target price on Qiagen from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, October 22nd. JPMorgan Chase & Co. restated a “neutral” rating and set a $52.00 target price (down from $55.00) on shares of Qiagen in a research report on Thursday, October 22nd. Citigroup reiterated a “neutral” rating and set a $52.00 target price (up from $45.00) on shares of Qiagen in a research report on Monday. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $48.00 target price on shares of Qiagen in a research report on Thursday, August 6th. Four analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $45.01.

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.